Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.

Immatics Biotechnologies GmbH, Tübingen, Germany; University Hospital Heidelberg, Heidelberg, Germany; Université de Genève, Genève, Switzerland; BioNTech AG, Mainz, Germany; Technion - Israel Institute of Technology, Haifa, Israel; Leiden University Medical Center, Rotterdam, The Netherlands; University Hospital Herlev, Herlev, Denmark; Leiden University Medical Center, Leiden, The Netherlands; Vall d’Hebron University Hospital, Barcelona, Spain; University of California San Francisco, San Francisco, CA; University of Southampton, Southampton, United Kingdom; BCN Peptides S.A., Barcelona, Spain; Ringhospitalet, Copenhagen, Denmark; University of Tübingen, Tübingen, Germany.